Final destination.

A look at a VA cohort of almost 31 million patients indicates that surviving a heme malignancy roughly doubles to triples the risk of developing a subsequent H&N cancer and lowers the risk of surviving it. | Mowery, JAMA Otolaryngol Head Neck Surg 2019